Skip to Content
Merck
CN

S8001

CpGenome Human Methylated & Non-Methylated DNA Standard Set

Synonym(s):

DNA Standard Set, Methylated DNA Standard Set, Non-Methylated DNA Standards

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

NACRES:
NA.84
UNSPSC Code:
41106310
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

Application

Purified from HCT116 DKO cells that contain genetic knockouts of DNA methyltransferases, DNMT1 (-/-) & DNMT3b (-/-) & have <5% methylated DNA.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

CpGenome Human Methylated & Non-methylated DNA Standards are purified from HCT116 DKO cells that contain genetic knockouts of DNA methyltransferases, DNMT1 (-/-) and DNMT3b (-/-) , and have less than 5% methylated DNA. The CpGenome Human Methylated DNA Standard has been methylated enzymatically at all CpG dinucleotides by M. SssI methyltransferase. These standards are intended for use as positive and negative controls in gene methylation studies, such as bisulfite conversion of DNA with the CpGenome Turbo Bisulfite Modification Kit (Cat. No. S7847). Bisulfite-modified DNA can be evaluated by methylation-specific PCR (MSP) technology using the CpG WIZ amplification kits.

Materials Provided:
Two vials, each containing 5 μg (20 μl) of CpGenome Human Non-Methylated DNA Standard or 5 μg (20 μl) of CpGenome Human Methylated DNA Standard, at a concentration of 250 ng/μL.

Validation:
Methylation-specific PCR (MSP) was performed on the DNA after bisulfite modification with the CpGenome Turbo Bisulfite kit (Cat. No. S7847). Three sets of primers from the CpG WIZ BRCA1 amplification kit (Cat. No. S7830) were used in this assay: the U primer set, which anneals to unmethylated bisulfite-modified DNA; M primers, which anneal to methylated bisulfite-modified sequences; and W primers, which anneal to unmethylated or methylated DNA that has not undergone bisulfite modification. Only the M primers generated product for the methylated DNA standard, and only the U primer set amplified the unmethylated Standard.

CpGenome and CpG WIZ are trademarks of Serologicals Corporation. CpG WIZ Methylation Products apply to technologies exclusively licensed from The Johns Hopkins University School of Medicine. Methylation-specific PCR (MSP) technology is covered under U.S. Patent # 5,786,146.

Storage Class

10 - Combustible liquids

Regulatory Information

高风险级别生物产品-Merck
This item has

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Related Content

DNA methylation is an important epigenetic mechanism regulating gene silencing, imprinting, embryonic development, and chromosome stability. DNA methylation occurs on the 5 carbon position of cytosine residues mainly within CpG dinucleotides to form 5-methylcytosines (5-mC). The reaction is catalyzed by DNA methyltransferases (DNMTs). 5-methylcytosines residues may also be hydroxylated by TET enzymes to form 5-hydroxymethylcytosine (5-hmC), which has differing roles from 5-mC. EMD Millipore provides robust tools that enable you to not only detect and quantify 5-mC and 5-hmC, but also to accurately distinguish between these modifications.

Cancer is a complex disease manifestation. At its core, it remains a disease of abnormal cellular proliferation and inappropriate gene expression. In the early days, carcinogenesis was viewed simply as resulting from a collection of genetic mutations that altered the gene expression of key oncogenic genes or tumor suppressor genes leading to uncontrolled growth and disease (Virani, S et al 2012). Today, however, research is showing that carcinogenesis results from the successive accumulation of heritable genetic and epigenetic changes. Moreover, the success in how we predict, treat and overcome cancer will likely involve not only understanding the consequences of direct genetic changes that can cause cancer, but also how the epigenetic and environmental changes cause cancer (Johnson C et al 2015; Waldmann T et al 2013). Epigenetics is the study of heritable gene expression as it relates to changes in DNA structure that are not tied to changes in DNA sequence but, instead, are tied to how the nucleic acid material is read or processed via the myriad of protein-protein, protein-nucleic acid, and nucleic acid-nucleic acid interactions that ultimately manifest themselves into a specific expression phenotype (Ngai SC et al 2012, Johnson C et al 2015). This review will discuss some of the principal aspects of epigenetic research and how they relate to our current understanding of carcinogenesis. Because epigenetics affects phenotype and changes in epigenetics are thought to be key to environmental adaptability and thus may in fact be reversed or manipulated, understanding the integration of experimental and epidemiologic science surrounding cancer and its many manifestations should lead to more effective cancer prognostics as well as treatments (Virani S et al 2012).

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service